NIH R01 · 2024
Expanding the cancer paralog genetic interaction map to enable precision oncology
PROJECT SUMMARY/ABSTRACT Recent advances in targeted therapies have prolonged the survival of non-small cell lung cancer patients. However, lung cancer still remains the leading cause of cancer deaths in the U.S. and worldwide, and the 5-year survival rate for non-small cell lung cancer is a dismal 24%. For many tumors, drug-targetable mutations are not identified, limiting therapeutic options to chemotherapy or immune checkpoint inhibitors. For those that do have identified druggable biomarkers, such as EGFR mutations, acquired resistance is near-universal problem. To make progress in extending lung cancer patient survival, it is necessary to identify new targets beyond those that are…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.